In contrast, no reactivity was observed against HLA-DR-unmatched ROR1+ HSC3 cells, suggesting that T cells reacted to the tumor in the context of the HLA-DR–peptide–T cell receptor interaction. This evidence concerns the gene TBXT and neoplasm.